Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Quin

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Ophthalmology|August 27, 2014
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX studyMark C Gillies, Lyndell L Lim, Anna Campain, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Journal of Medicinal Chemistry|September 15, 1995
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonistsJ J Edmunds, S Klutchko, J M Hamby, et al.
Journal of Medicinal Chemistry|January 1, 1992
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitorsA M Doherty, I Sircar, B E Kornberg, et al.
Journal of Medicinal Chemistry|November 1, 1991
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtypeC J Blankley, J C Hodges, S R Klutchko, et al.
Ophthalmology. Retina|April 25, 2019
Development of New Proliferative Diabetic Retinopathy in the BEVORDEX TrialHemal Mehta, Lyndell L Lim, Vuong Nguyen, et al.
BMC Medicine|August 22, 2021
Correction to: Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemicTerence J Quin, Jennifer K Burton, Ben Carter, et al.
Journal of Medicinal Chemistry|October 28, 1997
C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in miceD J McNamara, E Dobrusin, D M Leonard, et al.
Human Mutation|March 24, 2009
Planning the human variome project: the Spain reportJim Kaput, Richard G H Cotton, Lauren Hardman, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Ophthalmology|August 27, 2014
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX studyMark C Gillies, Lyndell L Lim, Anna Campain, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Journal of Medicinal Chemistry|September 15, 1995
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonistsJ J Edmunds, S Klutchko, J M Hamby, et al.
Journal of Medicinal Chemistry|January 1, 1992
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitorsA M Doherty, I Sircar, B E Kornberg, et al.
Journal of Medicinal Chemistry|November 1, 1991
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtypeC J Blankley, J C Hodges, S R Klutchko, et al.
Ophthalmology. Retina|April 25, 2019
Development of New Proliferative Diabetic Retinopathy in the BEVORDEX TrialHemal Mehta, Lyndell L Lim, Vuong Nguyen, et al.
BMC Medicine|August 22, 2021
Correction to: Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemicTerence J Quin, Jennifer K Burton, Ben Carter, et al.
Journal of Medicinal Chemistry|October 28, 1997
C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in miceD J McNamara, E Dobrusin, D M Leonard, et al.
Human Mutation|March 24, 2009
Planning the human variome project: the Spain reportJim Kaput, Richard G H Cotton, Lauren Hardman, et al.
Pageof 5